| India | Turchia | Austria | |
| Terapia biologica | da $1,800 | da $5,500 | da $20,000 |
| Radioterapia per il cancro colorettale | da $3,200 | da $7,000 | da $12,000 |
| Immunoterapia con Keytruda (Pembrolizumab) | da $3,500 | da $3,300 | da $15,000 |
| Chemioterapia per carcinoma mammario | da $3,500 | da $1,200 | da $15,000 |
| Chemioterapia | da $550 | da $2,430 | da $2,500 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Linfoma di Hodgkin. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Linfoma di Hodgkin e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Linfoma di Hodgkin.
Il medico è un ematologo-oncologo altamente esperto presso l'HCG Manavata Cancer Centre, Nashik, con oltre 13 anni di esperienza in leucemia, mieloma multiplo e trapianto di midollo osseo. <\/p>
Laureato con un MBBS presso il Grant Medical College e Sir JJ Hospital, il medico ha ulteriormente perseguito un MD in Patologia presso il Lokmanya Tilak Municipal Medical College, Sion, e Mumbai. <\/p>
Inoltre, il medico possiede un DM in Ematologia Clinica dal Medical College, Calcutta, e ha ricevuto premi per professionalità e duro lavoro, sottolineando la sua reputazione come specialista competente e qualificato.<\/p>
Il medico è specialista in oncoematologia con un focus sul trapianto di midollo osseo. Ha una vasta esperienza nel trattamento di malignità ematologiche complesse ed è abile nell'eseguire procedure di trapianto avanzate. Il medico ha contribuito a numerosi studi clinici e ha pubblicato diversi articoli di ricerca su riviste mediche prestigiose. È riconosciuto per la sua esperienza nella gestione di pazienti adulti e pediatrici, garantendo cure personalizzate e all'avanguardia.<\/p>
Il medico è un ematologo-oncologo pediatrico con specializzazione nel trapianto di midollo osseo. Ha una vasta esperienza nel trattamento di disturbi del sangue complessi e tumori nei bambini. Il suo focus clinico include la gestione della leucemia pediatrica, del linfoma e di altre malignità ematologiche. Il medico è riconosciuto per la sua esperienza nell'esecuzione di trapianti di midollo osseo e ha contribuito ai progressi nell'oncologia pediatrica attraverso la ricerca clinica e l'innovazione.<\/p>
Treatment success rates for Hodgkin's lymphoma in India range from 78% to 84% five-year survival. Early-stage cases (I and II) show success rates exceeding 90%. Outcomes remain competitive with Western standards due to advanced diagnostics like PET-CT and targeted immunotherapy protocols available in JCI-accredited hospitals.
Bookimed Expert Insight: Patient volume serves as a major quality indicator in India. Manipal Hospitals and Apollo Hospital Indraprastha handle over 1,000,000 patients annually. Large-scale centers often provide faster access to PET-CT imaging and hematologists like Dr. Girish Badarkhe. This helps avoid treatment delays that could otherwise impact survival rates.
Patient Consensus: Patients emphasize that early diagnosis and a clear treatment plan are more important than statistics. They note that managing the emotional burden and logistical needs, like frequent scans, is crucial for a smooth recovery.
Qualified lymphoma specialists in India hold advanced super-specialty degrees like DM or DNB in Medical Oncology or Clinical Hematology. These experts complete a multi-tier pathway. This includes an MBBS and a 3-year MD followed by a 3-year residency in hematologic malignancies.
Bookimed Expert Insight: While many search for general oncologists, the best outcomes for Hodgkin's lymphoma in India are found with DM-level hematology-oncologists. Specialists like Dr. Girish Badarkhe at HCG Manavata hold specific DM credentials in Clinical Hematology. This deep specialization is vital because these doctors focus exclusively on blood cancers rather than solid tumors.
Patient Consensus: Patients emphasize that treatment quality improves significantly when care is managed at centers with both oncology and specialized hematopathology expertise. They note it is important to confirm the doctor regularly treats lymphoma cases rather than just holding a senior consultant title.
Advanced CAR T-cell therapies are commercially available and indigenously manufactured in India. Domestic products like NexCAR19 and Qartemi are approved by the CDSCO. These therapies treat relapsed blood cancers at over 30 specialized centers. Major hubs include hospitals in Mumbai, Delhi, and Bengaluru.
Bookimed Expert Insight: India has become a global hub for cell therapy by reducing the logistical chain. While Western therapies cost over $400,000, domestic production in Bangalore and Mumbai centers significantly lowers barriers. Facilities like Manipal Hospitals even use IBM Watson to help cross-reference these advanced treatment protocols for optimal patient selection.
Patient Consensus: Patients note that while CAR T-cell therapy is a breakthrough, it remains a specialized option available only in major metro centers. Many emphasize that navigating the strict eligibility checks and securing a spot at a high-volume center is the most critical first step.
Hodgkin's lymphoma treatment in India causes temporary side effects like nausea, fatigue, and hair loss. Long-term risks include lung or heart issues. Indian oncologists manage these using advanced anti-nausea drugs, G-CSF injections for immunity, and precise radiation techniques to protect healthy tissue.
Bookimed Expert Insight: India's JCI-accredited centers like Artemis and Manipal Hospitals leverage high patient volumes to refine supportive care. Leading oncologists like Dr. Girish Badarkhe often use high-quality generic versions of growth factors and anti-emetics. This significantly lowers the cost of managing side effects while maintaining international efficacy standards.
Patient Consensus: Patients note that fatigue and steroid-related mood swings are challenging. They emphasize that early use of medicated mouthwashes and reporting numbness in extremities helps manage treatment successfully.
Indian oncologists design Hodgkin lymphoma plans using a data-driven framework. They integrate Indian Council of Medical Research (ICMR) and global guidelines. Decisions rely on precise node biopsies and PET-CT staging. Doctors finalize strategies based on subtype, risk markers, and organ function to ensure high cure rates.
Bookimed Expert Insight: Bookimed data shows Indian oncology networks like Manipal Hospitals and HCG Manavata leverage specialized technology for decision-making. Manipal Goa Hospital uses IBM Watson for Oncology to cross-reference cases against millions of data points. This AI-assisted approach helps hematologists like Dr. Mallikarjun Kalashetty select the most effective drug regimens for complex variants.
Patient Consensus: Patients note that doctors frequently adjust the number of chemotherapy cycles based on how the tumor reacts to the first two rounds. They emphasize the importance of discussing whether radiation will follow chemotherapy to better plan their long-term recovery.
Leading Indian hospitals for Hodgkin's lymphoma include Manipal Hospitals, Apollo Hospital Indraprastha, and Medanta Hospital. These centers offer precise diagnostics like PET-CT and flow cytometry. Specialized care involves immunotherapy, targeted chemotherapy, and bone marrow transplants performed in JCI-accredited facilities.
Bookimed Expert Insight: Patient volume often signals where the most complex lymphomas are managed. Manipal Hospitals and Apollo Hospital Indraprastha serve over 1,000,000 patients each annually. This high volume allows their tumor boards to see diverse relapsed cases. This experience is critical for choosing the right second-line therapy.
Patient Consensus: Patients emphasize choosing high-volume cancer centers rather than general hospitals. They note it is important to bring original biopsy slides for a secondary pathology opinion.
Plan for a stay between 2 and 10 months in India for Hodgkin's lymphoma treatment. Total duration depends on your cancer stage and prescribed chemotherapy cycles. Early-stage cases generally require 2 to 4 months. Advanced cases or stem cell transplants may extend stays up to 10 months.
Bookimed Expert Insight: Data shows Indian centers like Manipal Hospitals and Apollo Hospital Indraprastha manage over 1,000,000 patients annually. Large networks often provide in-house PET-CT and biopsy services. This can reduce your initial diagnostic stay from 14 days to just 5 days. Choosing a facility with integrated labs helps you start the first chemotherapy cycle much faster.
Patient Consensus: Patients note that bringing original biopsy slides and pathology reports from home prevents redundant testing. Most find it easier to stay in serviced apartments between cycles rather than remaining in the hospital.
Indian oncology centres report a 5-year survival rate of 83.6% for Hodgkin lymphoma. This reflects high standards in haematology. Standard chemotherapy regimens achieve a 93.5% overall response rate. Early-stage cases yield complete response rates over 92% at JCI-accredited facilities in Delhi, Mumbai, and Bengaluru.
Bookimed Expert Insight: India excels in treating refractory cases through mid-range centres like HCG Manavata. This centre manages 75,000+ patients annually. These institutions provide CAR T-cell therapy and haploidentical stem cell transplants. Such complex interventions often cost 2 to 5 times less than in Western Europe or Australia.
Patient Consensus: Patients find India treats Hodgkin lymphoma with high cure rates up to 95%. Remission is typical within 5 years. Waiting periods of 1 to 2 months may occur at major hospitals. Younger patients below 30 years report particularly favourable recovery prospects during chemotherapy sessions.
Indian oncologists treating Hodgkin lymphoma hold international qualifications. Most senior specialists have completed fellowships at institutions like MD Anderson or Royal Marsden. They often hold European Society for Medical Oncology (ESMO) board certifications. Major centres follow global NCCN and ESMO clinical guidelines.
Bookimed Expert Insight: Indian cancer centres like HCG Manavata Cancer Centre maintain a US-FDA audited research wing. This level of regulatory oversight proves their clinical data and treatment protocols meet strict international benchmarks. High-volume specialists here often manage more lymphoma cases in a single year. This is more than many Western doctors see in five.
Patient Consensus: Patients note that Indian oncologists are highly trusted globally. Many travel from the Middle East to India. They seek the expertise in ABVD and AAVD chemotherapy protocols.
India uses chemotherapy, radiotherapy, and immunotherapy to treat Hodgkin lymphoma. Specialist centres like HCG Manavata Cancer Centre offer specialised technical approaches. These include CAR T-cell therapy and allogeneic bone marrow transplantation. They treat complex or relapsed cases. Treatment protocols typically follow international medical standards.
Bookimed Expert Insight: Indian oncology centres increasingly integrate PET-CT and IBM Watson for Oncology. This helps them reach 96% diagnostic accuracy. Major networks like Manipal Hospitals serve over 2,000,000 international patients annually. This massive volume allows specialists to manage complex cases that smaller regional clinics rarely see.
Patient Consensus: Patients note that Hodgkin lymphoma is highly curable in India. Success rates reach 87–90% even in advanced stages. Patients receiving care in Mumbai or Delhi commonly seek second opinions for relapsed cases.
Indian hospitals offer comprehensive support including dedicated international patient desks, medical visa assistance, and free airport transfers. Specialists like Dr Deenadayalan Munirathnam and Dr Girish Badarkhe provide specialised care. Facilities such as Aster CMI and Manipal Hospitals cater to more than 2,000,000 patients annually with tailored logistics.
Bookimed Expert Insight: Major networks like Apollo and Manipal handle millions of international patients annually. This sets a standard where personal coordinators are included. Patients should look for JCI-accredited centres like Artemis or Apollo. These align with Australian healthcare quality benchmarks and provide smoother post-surgical follow-up.
Patient Consensus: International patients note that clinical care for lymphoma in India is swift. However, proactive logistical planning for housing and financial crowdfunding is often necessary. Detailed peer support groups and social workers are common in high-volume regional hubs.